Medivation (Medivation) Operating Income : $-257 Mil (TTM As of Jun. 2016)

View and export this data going back to 1996. Start your Free Trial

What is Medivation Operating Income?

Medivation's Operating Income for the three months ended in Jun. 2016 was $-626 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2016 was $-257 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Medivation's Operating Income for the three months ended in Jun. 2016 was $-626 Mil. Medivation's Revenue for the three months ended in Jun. 2016 was $206 Mil. Therefore, Medivation's Operating Margin % for the quarter that ended in Jun. 2016 was -303.47%.

Medivation's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Medivation's annualized ROC % for the quarter that ended in Jun. 2016 was -151.65%. Medivation's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2016 was -4,142.00%.

Medivation Operating Income Historical Data

The historical data trend for Medivation's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivation Operating Income Chart

Medivation Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Operating Income

Get a 7-Day Free Trial

-42.93

-26.21

-22.24

281.85

414.61

Medivation Quarterly Data
	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16
Operating Income	Get a 7-Day Free Trial															53.66	138.99	221.40	8.08	-625.64

Medivation Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-257 Mil.

Medivation (NAS:MDVN) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Medivation's annualized ROC % for the quarter that ended in Jun. 2016 is calculated as:

	ROC % (Q: Jun. 2016 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2016 )	+	Invested Capital (Q: Jun. 2016 ))	/ count )
=	-2502.564 * ( 1 - 35.49% )	/	( (931.761	+	1197.288)	/ 2 )
=	-1614.4040364	/	1064.5245
=	-151.65 %

where

	Invested Capital		(Q: Mar. 2016 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1325.482	-	76.36	-	( 317.361	-	max(0, 127.029	-	529.51	+	317.361	))
=	931.761

	Invested Capital		(Q: Jun. 2016 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1659.507	-	135.026	-	( 327.193	-	max(0, 140.104	-	605.605	+	327.193	))
=	1197.288

Note: The Operating Income data used here is four times the quarterly (Jun. 2016) data.

2. Joel Greenblatt's definition of Return on Capital:

Medivation's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2016 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2016 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2016		Q: Jun. 2016
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-2502.656	/	( ( (59.849 + max(-101.363, 0))	+	(60.994 + max(-88.875, 0)) )	/	2 )
=	-2502.656	/	( ( 59.849	+	60.994 )	/	2 )
=	-2502.656	/	60.4215
=	-4,142.00 %

where Working Capital is:

	Working Capital		(Q: Mar. 2016 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	25.556)	-	(76.36	+	0	+	50.559)
=	-101.363

	Working Capital		(Q: Jun. 2016 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	51.102)	-	(135.026	+	0	+	4.951)
=	-88.875

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2016) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Medivation's Operating Margin % for the quarter that ended in Jun. 2016 is calculated as:

Operating Margin %	=	Operating Income (Q: Jun. 2016 )	/	Revenue (Q: Jun. 2016 )
	=	-625.641	/	206.165
	=	-303.47 %

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Medivation Operating Income Related Terms

Thank you for viewing the detailed overview of Medivation's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Medivation (Medivation) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivation Inc (NAS:MDVN) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.medivation.com/

Medivation Inc was formed in Delaware in October 1995. The Company is a biopharmaceutical company engaged in the rapid development of novel small molecule drugs to treat diseases for which there are limited treatment options. Together with its collaboration partner Astellas Pharma Inc., or Astellas, the Company is developing XTANDI enzalutamide capsules. Together with Astellas, it is also conducting multiple trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy, or pre-chemotherapy mCRPC patients, and in patients with breast cancer. Based on the positive results of the AFFIRM trial, the Company has exercised its right under its collaboration agreement with Astellas to co-promote XTANDI in the U.S., should it receive marketing approval. Their subsidiaries are Medivation Prostate Therapeutics Inc or MPT, Medivation Neurology Inc or MNI, Medivation Technologies Inc, or MTI, Medivation Field Solutions, Inc., or MFSI, and Medivation Services, Inc., or MSI. MPT holds the intellectual property rights covering XTANDI. MNI holds the intellectual property rights covering dimebon, which was in development for Alzheimer's disease and Huntington disease under its former collaboration with Pfizer. MTI holds the intellectual property rights covering its early-stage technologies. MFSI provides commercialization services to the Company, and MSI provides research and development services. It has received "Fast Track" designation from the U.S. Food and Drug Administration for the post-docetaxel indication. The Company is conducting this program in collaboration with Astellas. The Company is subject to extensive regulation by the Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.

Executives

W Anthony Vernon	director	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, NEW YORK NY 10018
Marion Mccourt	officer: Chief Operating Officer	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Tseli Lily Yang	officer: VP, Finance and Accounting	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Mohammad Hirmand	officer: Interim Chief Medical Officer	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
David Hung	director, officer: President and CEO	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Dawn Svoronos	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Wendy L Yarno	director
Jennifer Jarrett	officer: Chief Financial Officer	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Kim D Blickenstaff	director	C/O MEDIVATION, INC., 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94105
Powell Andrew Kenneth William	officer: SVP, General Counsel & Crp Sec	C/O COLLAGENEX PHARMACEUTICALS, INC., 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
Patrick Machado	director	201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Kathryn E Falberg	director	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Rick Bierly	officer: CFO (former)	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Joseph M Lobacki	officer: Chief Commercial Officer	C/O MICROMET, INC., 9201 CORPORATE BLVD., SUITE 400, ROCKVILLE MD 20850
Jennifer J Rhodes	officer: GC & Corporate Secretary	C/O ADAMAS PHARMACEUTICALS INC., 1900 POWELL ST., SUITE 750, EMERYVILLE CA 94608